Logo

NAGE

Niagen Bioscience Inc

NAGE

Niagen Bioscience Inc • NASDAQ
$6.77 ▼ -1.74% (-0.12)
Market Cap $540.29 M
52w High $14.69
52w Low $5.16
Dividend Yield 0%
P/E 28.21
Volume 272.08K
Outstanding Shares 79.81M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $33.986M ▲ $17.692M ▲ $4.578M ▲ 13.47% ▲ $0.057 ▲ $4.995M ▲
Q2-2025 $31.117M ▲ $17.041M ▲ $3.609M ▼ 11.598% ▼ $0.045 ▼ $3.54M ▼
Q1-2025 $30.481M ▲ $14.559M ▲ $5.063M ▼ 16.61% ▼ $0.065 ▼ $5.14M ▼
Q4-2024 $29.125M ▲ $11.086M ▼ $7.179M ▲ 24.649% ▲ $0.093 ▲ $7.469M ▲
Q3-2024 $25.58M $14.638M $1.878M 7.342% $0.02 $1.968M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $64.138M ▲ $98.139M ▲ $27.463M ▲ $70.676M ▲
Q2-2025 $60.322M ▲ $91.525M ▲ $27.33M ▲ $64.195M ▲
Q1-2025 $55.464M ▲ $81.337M ▲ $25.992M ▲ $55.345M ▲
Q4-2024 $44.508M ▲ $68.278M ▲ $22.184M ▲ $46.094M ▲
Q3-2024 $32.246M $56.522M $22.153M $34.369M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $4.578M ▲ $3.692M ▲ $-24K ▲ $148K ▼ $3.816M ▼ $3.668M ▲
Q2-2025 $3.609M ▼ $1.25M ▼ $-135K ▼ $3.743M ▲ $4.858M ▼ $1.115M ▼
Q1-2025 $5.063M ▼ $7.883M ▼ $-32K ▲ $3.105M ▼ $10.956M ▼ $7.851M ▼
Q4-2024 $7.179M ▲ $8.583M ▲ $-69K ▼ $3.748M ▲ $12.262M ▲ $8.514M ▲
Q3-2024 $1.878M $3.495M $-21K $1.039M $4.513M $3.454M

Five-Year Company Overview

Income Statement

Income Statement Revenue is still very small but has been steadily creeping higher over the past few years. Gross margins look healthy, which means the core product is priced with a good mark‑up over costs. The business moved from losses to roughly break‑even and then to a modest profit most recently, showing improving cost discipline and operating leverage. That said, at this small scale, earnings can swing quickly with any change in demand or spending, so profitability should be viewed as early and still fragile rather than firmly established.

Balance Sheet

Balance Sheet The balance sheet is simple and relatively clean. The company holds a meaningful portion of its assets in cash and carries essentially no debt, which reduces financial risk and interest burden. Equity has been building as losses have narrowed and then turned to profit, suggesting gradual strengthening of the capital base. However, the overall asset base is small, reflecting a company that remains in an early, growth‑oriented phase rather than a mature, asset‑heavy business.

Cash Flow

Cash Flow Operating cash flow has shifted from negative to consistently positive in the last couple of years, which is a key milestone for any biotech‑adjacent company. Because capital spending is minimal, most operating cash effectively becomes free cash flow, giving management flexibility to fund research, marketing, and partnerships without heavy borrowing. Still, the cash cushion, while helpful, is not huge, so any step‑up in clinical or commercial investment would need to be watched for its impact on future cash burn.

Competitive Edge

Competitive Edge Niagen Bioscience has carved out a focused niche around NAD+ science and nicotinamide riboside. Its moat rests on several pillars: a sizable patent portfolio protecting its core ingredient, a large body of clinical and preclinical data, and early, sustained branding around Tru Niagen. The vertically integrated model—selling direct to consumers, supplying ingredients to partners, and offering analytical services—deepens its role in this ecosystem. On the risk side, the company is still heavily concentrated in one main technology area, operates in a space where scientific narratives can shift, and faces ongoing competition from other NAD+ and healthy‑aging approaches, as well as regulatory scrutiny over health claims.

Innovation and R&D

Innovation and R&D Innovation is the center of the story. The company has invested in extensive human studies on Niagen, built collaborations with academic institutions worldwide, and continues to leverage external researchers to expand the science at relatively low internal cost. Newer initiatives, such as Niagen Plus for intravenous and injectable use, move the business closer to a medical‑grade, clinic‑based model with potentially higher value per patient. Longer term, the most ambitious frontier is pharmaceutical development for conditions like Parkinson’s and rare age‑related diseases. These programs, while promising, carry typical biotech risks: long timelines, high uncertainty of clinical outcomes, and potential need for significant additional funding or partnerships to reach full commercialization.

Summary

Niagen Bioscience is a small but increasingly disciplined company positioned at the intersection of dietary supplements, wellness clinics, and early‑stage pharmaceutical development, all centered on NAD+ biology. Financially, it has transitioned from steady losses to modest profitability and positive free cash flow, helped by strong gross margins and minimal capital needs, though its scale remains limited and inherently more volatile. Strategically, it enjoys meaningful scientific credibility, patent protection, and brand recognition around Niagen, with growing traction in higher‑touch offerings like Niagen Plus. The main opportunities lie in expanding adoption across consumer, clinic, and potential pharma channels; the main risks stem from scientific and regulatory uncertainty, concentration in a single core technology, and the execution demands of moving from a supplement‑led business toward regulated therapeutics.

NEWS

November 13, 2025 · 8:32 AM UTC

Niagen Bioscience Launches Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. Featuring Niagen® (Patented Nicotinamide Riboside)

Read more

November 12, 2025 · 7:52 PM UTC

Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVID

Read more

November 6, 2025 · 8:07 AM UTC

Niagen Bioscience Announces $10 Million Share Repurchase Program

Read more

November 4, 2025 · 4:02 PM UTC

Niagen Bioscience, Inc. Reports Third Quarter 2025 Financial Results and Reaffirms Increased Full Year Outlook

Read more

October 21, 2025 · 8:32 AM UTC

Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

Read more